Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. At1-2042
1. 335148-45-3
2. Ati-2042
3. Budiodarone [usan:inn]
4. Unii-f5y53150c8
5. F5y53150c8
6. At1-2042
7. [(2s)-butan-2-yl] 2-[3-[4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl]-1-benzofuran-2-yl]acetate
8. 2-benzofuranacetic Acid, 3-(4-(2-(diethylamino)ethoxy)-3,5-diiodobenzoyl)-, (1s)-1-methylpropyl Ester
9. (1s)-1-methylpropyl 2-(3-(4-(2-(diethylamino)ethoxy)-3,5-diiodobenzoyl)benzofuran-2-
10. (s)-sec-butyl 2-(3-(4-(2-(diethylamino)ethoxy)-3,5-diiodobenzoyl)benzofuran-2-yl)acetate
11. (2s)-butan-2-yl2-(3-[4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl]-1-benzofuran-2-yl)acetate
12. Budiodarone [usan]
13. (s)-ati 2042
14. Budiodarone [inn]
15. Budiodarone (usan/inn)
16. Budiodarone [who-dd]
17. Schembl1946426
18. Chembl2105631
19. Zxosvkycxltvgs-krwdzbqosa-n
20. Dtxsid301030142
21. Akos040750928
22. Db05519
23. Hy-14834
24. Cs-0003584
25. Ns00069738
26. D09590
27. Q4985107
28. (1s)-1-methylpropyl 2-(3-{4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl}benzofuran-2-yl)acetate
| Molecular Weight | 703.3 g/mol |
|---|---|
| Molecular Formula | C27H31I2NO5 |
| XLogP3 | 7 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 13 |
| Exact Mass | g/mol |
| Monoisotopic Mass | g/mol |
| Topological Polar Surface Area | 69 |
| Heavy Atom Count | 35 |
| Formal Charge | 0 |
| Complexity | 679 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Investigated for use/treatment in arrhythmia and atrial fibrillation.
Drugs in Development
Details:
ATI-2042 (budiodarone) is a potentially best-in-class mixed ion channel blocker. It is being evaluated for the treatment of symptomatic non-permanent atrial fibrillation.
Lead Product(s): Budiodarone
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: ATI-2042
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 16, 2024
Lead Product(s) : Budiodarone
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
XYRA Gains FDA Guidance on Atrial Fibrillation Management with Budiodarone
Details : ATI-2042 (budiodarone) is a potentially best-in-class mixed ion channel blocker. It is being evaluated for the treatment of symptomatic non-permanent atrial fibrillation.
Product Name : ATI-2042
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 16, 2024
Details:
ATI-2042 (budiodarone) is a potentially best-in-class mixed ion channel blocker. It is being evaluated for the treatment of symptomatic non-permanent atrial fibrillation.
Lead Product(s): Budiodarone
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: ATI-2042
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 26, 2024
Lead Product(s) : Budiodarone
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
XYRA Completes FDA Phase 2 Meeting on Budiodarone for Atrial Fibrillation Management
Details : ATI-2042 (budiodarone) is a potentially best-in-class mixed ion channel blocker. It is being evaluated for the treatment of symptomatic non-permanent atrial fibrillation.
Product Name : ATI-2042
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 26, 2024
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
93
PharmaCompass offers a list of Budiodarone API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Budiodarone manufacturer or Budiodarone supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Budiodarone manufacturer or Budiodarone supplier.
PharmaCompass also assists you with knowing the Budiodarone API Price utilized in the formulation of products. Budiodarone API Price is not always fixed or binding as the Budiodarone Price is obtained through a variety of data sources. The Budiodarone Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Budiodarone manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Budiodarone, including repackagers and relabelers. The FDA regulates Budiodarone manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Budiodarone API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Budiodarone supplier is an individual or a company that provides Budiodarone active pharmaceutical ingredient (API) or Budiodarone finished formulations upon request. The Budiodarone suppliers may include Budiodarone API manufacturers, exporters, distributors and traders.
Budiodarone Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Budiodarone GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Budiodarone GMP manufacturer or Budiodarone GMP API supplier for your needs.
A Budiodarone CoA (Certificate of Analysis) is a formal document that attests to Budiodarone's compliance with Budiodarone specifications and serves as a tool for batch-level quality control.
Budiodarone CoA mostly includes findings from lab analyses of a specific batch. For each Budiodarone CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Budiodarone may be tested according to a variety of international standards, such as European Pharmacopoeia (Budiodarone EP), Budiodarone JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Budiodarone USP).
